Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
ApexOnco Front Page
Recent articles
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
Emilta-L continues to show worse efficacy than a rival ADC discontinued by Pfizer.
Early data with ELVN-001 hold up well against olverembatinib and TERN-701.
Emrelis becomes the first drug for cMet-positive NSCLC, but only for the highest expressers.
The company deprioritises its lead project, naporafenib, shifting to two Joyo-originated assets.
IBI3020 beats Chengdu Kanghong's KH815 into clinical trials.
GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.
